top of page
  • Writer's pictureKNoW Monitors

Progress Update l January 2023

From a Sandia National Laboratory news release:


Detected Chemical Signatures:

Working with our KNoW Biological CRADA partner, Sandia tested our Volatile Organic Compound (VOC) detection technology and demonstrated that it could identify chemical signatures of epileptic seizures emitted through the skin. The test was validated against, and produced similar results to, canine detection. Sandia's approach, which can be implemented as a microsystem, has the potential to identify seizures prior to onset. This successful test paves the way for Sandia to explore novel national security applications for our VOC detection capabilities.

One of the Sandia scientists recently confided to me: “The projects we work on are like our children…and you’re not supposed to love one child more than the others. But without exception, we all love the Know project more than anything we’ve ever done.” Nice to hear, right?

Anyway, it’s 2023, and it’s time to update our progress.


As you may tell from the Sandia quote, we now have a prototype that works! This, of course, is huge. We have shown the ability to collect, test, and identify our targeted VOCs. In samples supplied by epilepsy patients, we were able to show the presence of Menthone in a sample taken fifteen minutes before a seizure occurred. Just what we were hoping!


So we have moved from the first phase — the development of the device — into the second phase — testing of the device. We are in the process of creating a comprehensive plan, taking us from internal testing on a relatively small scale to a wider-reaching program that will be used to submit the device for regulatory approval if needed. This will involve our primary physician, Edward Maa, MD, a renowned epileptologist in Denver, Colorado.

In addition, we will start a product design endeavor to make our device easily wearable for our users. Currently, the device is lab worthy but needs some strategic redesign for end-users.


We are concentrating our efforts on finishing the epilepsy detection device. But we have always focused on the enormous opportunity of being an integral part of the next generation of self-health monitoring using our VOC detection application.


We have been proactive in pursuing patent protection for both the specific-use device and the overall health monitor and now have patents for the epilepsy device and the general health monitor. We own four patents and have seven more in the review process with the USPTO.


Comentarios


bottom of page